Xiao, Xiangling http://orcid.org/0000-0002-5352-3441
Shi, Jie
He, Chuan
Bu, Xia
Sun, Yishuang
Gao, Minling
Xiang, Bolin
Xiong, Wenjun
Dai, Panpan
Mao, Qi
Xing, Xixin
Yao, Yingmeng
Yu, Haisheng
Xu, Gaoshan
Li, Siqi
Ren, Yan
Chen, Baoxiang
Jiang, Congqing
Meng, Geng http://orcid.org/0000-0003-3335-2283
Lee, Yu-Ru http://orcid.org/0000-0001-6592-6806
Wei, Wenyi http://orcid.org/0000-0003-0512-3811
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Xie, Conghua http://orcid.org/0000-0001-6623-9864
Zhang, Jinfang http://orcid.org/0000-0001-8487-6007
Article History
Received: 28 September 2022
Accepted: 10 May 2023
First Online: 19 May 2023
Competing interests
: G.J.F. has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, Eli Lilly, and Novartis. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, Trillium, GV20, IOME, and Geode. G.J.F. has equity in Nextpoint, Triursus, Xios, iTeos, IgM, GV20, Invaria, and Geode. W.W. is a co-founder and consultant for ReKindle Therapeutics. The remaining authors declare no other competing interests.